½ÃÀ庸°í¼­
»óǰÄÚµå
1193135

¿Ã¶õÀÚÇÉ ½ÃÀå : ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2031³â)

Olanzapine Market By Application, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 229 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿Ã¶õÀÚÇÉÀº ºñÁ¤Çü Ç×Á¤½Åº´ ¾à¹°·Î ÁÖ·Î Á¤½Å ºÐ¿­Áõ°ú ¾ç±Ø¼º Àå¾ÖÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.

Á¤Á¦, ÁÖ»çÁ¦, ºØ±« Á¤Á¦ÀÇ ÇüÅ·ΠÁ¦°øµË´Ï´Ù. µµÆÄ¹Î°ú ¼¼·ÎÅä´ÑÀÇ ±ÕÇüÀ» Àâ°íÀÎÁö, ±âºÐ, ÇൿÀ» °­È­ÇÕ´Ï´Ù. ¿Ã¶õÀÚÇÉÀº 13¼¼ ÀÌ»óÀÇ ¼ºÀΰú û¼Ò³â¿¡¼­ »ç°íÀå¾Ö¿Í ÀÌ»óÇÑ »ý°¢, »î¿¡ ´ëÇÑ °ü½ÉÀÇ »ó½Ç, °­ÇÑ °¨Á¤°ú ºÎÀûÀýÇÑ °¨Á¤À» ÀÏÀ¸Å°´Â Á¤½Å ÁúȯÀÎ Á¤½ÅºÐ¿­ÁõÀÇ Áõ»ó Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ 13¼¼ ÀÌ»óÀÇ ¼ºÀΰú û¼Ò³â±â¿¡¼­ Á¶º´, ºñ¾Ö ¹× ±âŸ ºñÁ¤»óÀûÀÎ ±âºÐÀÇ ¿¡ÇǼҵ带 ÀÏÀ¸Å°´Â Á¶¿ïÁõÀÎ ¾ç±Ø¼º Àå¾ÖÀÇ Ä¡·á¿¡µµ »ç¿ëµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)´Â ȸ¿ø±¹ÀÇ Á¤½Å°Ç°­À» ÃËÁøÇϰí Á¤½ÅÀå¾Ö¸¦ ¿¹¹æÇϱâ À§ÇØ Á¤½Å°Ç°­ Çൿ °èȹÀ» ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ WHO°¡ ¹ßÇ¥ÇÑ ÁÖ¿ä »ç½Ç¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ÃßÁ¤ 3¾ï ¸íÀÌ ¿ì¿ïÁõ¿¡ 6,000¸¸ ¸íÀÌ ¾ç±Ø¼º Àå¾Ö¸¦ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ºÒ¾È Àå¾Ö´Â ¾î¸°À̺ÎÅÍ ¼ºÀαîÁö ÀÌȯµÇ´Â °¡Àå ÈçÇÑ Á¤½Å ÁúȯÀÔ´Ï´Ù. 4,400¸¸ ¸íÀÇ ¹Ì±¹ ¼ºÀÎÀÌ ºÒ¾È Àå¾ÖÀÇ ¿µÇâÀ» ¹Þ´Â °ÍÀ¸·Î Æò°¡µÇ°í ÀÖ½À´Ï´Ù. ºÒ¾È Àå¾Ö´Â ¸Å¿ì Ä¡·áÇϱ⠽¬¿î Áúº´ÀÓ¿¡µµ ºÒ±¸ÇÏ°í ºÒ¾È Àå¾Ö·Î °íÅë¹Þ´Â »ç¶÷µéÀÇ ¾à 1/3ÀÌ Ä¡·á¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. µû¶ó¼­, ÀÌ ½ÃÀåÀº ÁÖ·Î Á¤½ÅÁúȯÀÇ À¯º´·üÀÇ »ó½Â¿¡ ÀÇÇØ °ßÀεǰí ÀÖ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù.

¿Ã¶õÀÚÇÉÀÇ ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î Á¤½Å ºÐ¿­ÁõÀÇ ¼¼°è À¯º´·üÀÇ »ó½Â¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â 1¿ù Á¤½ÅºÐ¿­ÁõÀº Àü¼¼°è ¾à 2,400¸¸ ¸í, 300¸í Áß 1¸í(0.32%)À» ¾Î°í ÀÖ´Ù°í ÇÑ´Ù. ¶ÇÇÑ À§»ý°ü¸® ¹× ¿¹¹æÁ¶Ä¡ ºÎÁ·À¸·Î ÀÎÇÑ º´¿ø³» °¨¿°(HAI)ÀÇ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤½ÅÀå¾ÖÀÎÀ» À§ÇÑ Áø·á¼ÒÀÇ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ Á¤ºñµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¿Ã¶õÀÚÇÉÀÇ ³ôÀº °¡°Ý°ú ºÎÀÛ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ¹Ý´ë·Î, ÁÖ¿ä ¼±¼öµé¿¡ ÀÇÇÑ ½ÃÀå¿¡¼­ ¿Ã¶õÀÚÇÉÀÇ Á¦Ç° ½ÂÀÎ Áõ°¡¿Í ½ÅÈï °æÁ¦ ±¹°¡ÀÇ ³ôÀº ¼ºÀå °¡´É¼ºÀº ½ÃÀå ¼±¼öµé¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 6¿ù, ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ȸ»çÀÎ Alkermes plc.´Â ¼ºÀÎ Á¤½ÅºÐ¿­Áõ Ä¡·á ¹× ¼ºÀÎ ½Ö±Ø IÇü Àå¾Ö Ä¡·á, À¯Áö ´Üµ¶ ¿ä¹ý ¶Ç´Â ¸®Æ¬ ¶Ç´Â ¹ßÇÁ·Î»ê º¸Á¶ Ä¡·á·Î Á¶ ¶Ç´Â È¥ÇÕ ¿¡ÇǼҵåÀÇ ±Þ¼º Ä¡·á·Î LYBALVI (¿Ã¶õÀÚÇɰú »ç¹Ìµ¹ ÆÒ)ÀÇ ¹Ì±¹ ½Äǰ ÀǾ౹ (FDA)À» ¹Þ¾Ò½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ÁÖ¿ä ÅõÀÚ Æ÷ÄÏ
  • Porter's Five Forces ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø ¿äÀÎ
    • ¾ïÁ¦ ¿äÀÎ
    • ±âȸ
  • COVID-19 ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇ⠺м®

Á¦4Àå ¿Ã¶õÀÚÇÉ ½ÃÀå : ¿ëµµº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • Á¤½ÅºÐ¿­Áõ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ¾ç±Ø¼º Àå¾Ö
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ±âŸ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦5Àå ¿Ã¶õÀÚÇÉ ½ÃÀå : Åõ¿© °æ·Îº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • °æ±¸
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ºñ°æ±¸
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦6Àå ¿Ã¶õÀÚÇÉ ½ÃÀå : À¯Åë ä³Îº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • º´¿ø ¾à±¹
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀΰú ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ¾à±¹, ¼Ò¸Å ¾à±¹
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ¿Â¶óÀÎ Á¦°øÀÚ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦7Àå ¿Ã¶õÀÚÇÉ ½ÃÀå : Áö¿ªº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • ºÏ¹Ì
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ºÏ¹ÌÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Åõ¿© °æ·Îº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Åë ä³Îº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • À¯·´
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • À¯·´ÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Åõ¿© °æ·Îº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Åë ä³Îº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ¿µ±¹
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÁö¿ªÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Åõ¿©°æ·Îº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Åë ä³Îº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ÀϺ»
      • Áß±¹
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • LAMEA
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Åõ¿©°æ·Îº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Åëä³Îº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ºê¶óÁú
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ³²¾ÆÇÁ¸®Ä« °øÈ­±¹
      • ±âŸ LAMEA

Á¦8Àå ±â¾÷ Á¤¼¼

  • ¼Ò°³
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10°³»çÀÇ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÇÕÀÇ È÷Æ® ¸Ê
  • ÁÖ¿ä ¹ßÀü

Á¦9Àå ±â¾÷ ÇÁ·ÎÇÊ

  • Alkermes, Inc.
  • apotex inc.
  • Aurobindo Pharma Ltd
  • Eli Lilly and Company
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Å䷻Ʈ±×·ì
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Viatris
ksm 23.03.27

Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder. It is available in the form of a tablet, injectable, and a disintegrating tablet. It balances dopamine and serotonin to enhance cognition, mood, and behavior. Olanzapine is used to treat the symptoms of schizophrenia, which is a mental condition that causes disturbed or strange thinking, loss of interest in life, and strong or inappropriate emotions, in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder, which is a manic-depressive disorder, a condition that produces episodes of mania, sadness, and other abnormal moods, in adults and adolescents 13 years of age and older.

World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.

The growth of global olanzapine market is majorly driven by rise in prevalence of schizophrenia globally. For instance, in January 2022, according to World Health Organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) globally. In addition, increase in cases of Hospital Acquired Infections (HAI), owing to lack of sanitation and preventive measures, is a major factor responsible for the market growth. Furthermore, rise in the number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, high cost of olanzapine and side effects of olanzapine hinder the market growth. Conversely, rise in product approvals for olanzapine in market by key players and high growth potential in developing economies are anticipated to provide lucrative opportunities to the market players. For instance, in June 2021, Alkermes plc., a global biopharmaceutical company, received U.S. Food and Drug Administration (FDA) for its LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

The olanzapine market is segmented into application, route of administration, distribution channel, and region. On the basis of application, the market is segregated into schizophrenia, bipolar disorders, and others. By route of administration, the market is segmented into oral and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global olanzapine market are Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Bipolar Disorder
  • Others
  • Schizophrenia

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Alkermes, Inc.
    • apotex inc.
    • Aurobindo Pharma Ltd
    • Eli Lilly and Company
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Torrent Group
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Viatris

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Schizophrenia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Bipolar Disorder
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oral
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Parenteral
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: OLANZAPINE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Application
    • 7.2.3 North America Market size and forecast, by Route of Administration
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Application
    • 7.3.3 Europe Market size and forecast, by Route of Administration
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Application
    • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Application
    • 7.5.3 LAMEA Market size and forecast, by Route of Administration
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by Route of Administration
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Alkermes, Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 apotex inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Aurobindo Pharma Ltd
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Dr. Reddy's Laboratories Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Sun Pharmaceutical Industries Limited
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Torrent Group
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Teva Pharmaceutical Industries Limited
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Novartis AG
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Viatris
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦